Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.

Abstract

In a randomized double-blind cross-over trial we gave either 1-deamino-8-D-arginine vasopressin or placebo to 12 patients with uremia, hemorrhagic tendencies, and prolonged bleeding times. After vasopressin infusion, all patients had shortened bleeding times, with the effect lasting for at least four hours in most cases. Platelet count, platelet cyclic AMP levels, platelet retention on glass beads, plasma fibronectin, serum thromboxane B2 and residual prothrombin, hematocrit, and plasma osmolarity were unchanged after vasopressin. A consistent post-infusion increase in factor VIII coagulant activity and, to a lesser extent, in factor VIII-related antigen and ristocetin cofactor accompanied the shortening of bleeding time. In addition, vasopressin induced the appearance in plasma of larger von Willebrand-factor multimers than those present in the resting state. The compound was given to nine additional patients with acute or chronic renal failure and prolonged bleeding times, before major surgery or renal biopsy. In these patients, shortening of the bleeding time was associated with normal hemostasis. Our findings indicate that 1-deamino-8-D-arginine vasopressin can be used for temporary correction of bleeding time and may prevent surgical bleeding in patients with uremia.

• Authors: P M Mannucci, G Remuzzi, F Pusineri, R Lombardi, C Valsecchi, G Mecca, T S Zimmerman
• Journal: The New England journal of medicine (N Engl J Med) Vol. 308 Issue 1 Pg. 8-12 (Jan 06 1983) ISSN: 0028-4793 [Print] United States
• PMID: 6401193 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antigens
• von Willebrand Factor
• Arginine Vasopressin
• Factor VIII
• Fibrinogen
• Deamino Arginine Vasopressin

Topics

• Adult
• Antigens (analysis)
• Arginine Vasopressin (therapeutic use)
• Bleeding Time
• Clinical Trials as Topic
• Deamino Arginine Vasopressin (pharmacology, therapeutic use)
• Double-Blind Method
• Factor VIII (analysis, immunology)
• Female
• Fibrinogen (analysis)
• Hemorrhage (etiology, prevention & control)
• Humans
• Male
• Middle Aged
• Platelet Function Tests
• Postoperative Complications (prevention & control)
• Random Allocation
• Uremia (complications)
• von Willebrand Factor (analysis)